Carsten Nieder1,2, Astrid Dalhaug1, Ellinor Haukland1,2. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway. 2. Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Abstract
BACKGROUND AND AIM: The prognostic assessment of patients referred for palliative radiotherapy can be conducted by site-specific scores. A quick assessment that would cover the whole spectrum could simplify the working day of clinicians who are not specialists for a particular disease site. This study evaluated a promising score, the LabBM (validated for brain metastases), in patients treated for other indications. MATERIALS AND METHODS: The LabBM score was calculated in 375 patients by assigning 1 point each for C-reactive protein and lactate dehydrogenase above the upper limit of normal, and 0.5 points each for hemoglobin, platelets and albumin below the lower limit of normal. Uni- and multivariate analyses were performed. RESULTS: Median overall survival gradually decreased with increasing point sum (range 25.1-1.1 months). When grouped according to the original three-tiered model, excellent discrimination was found. Patients with 0-1 points had a median survival of 15.7 months. Those with 1.5-2 points had a median survival of 5.8 months. Finally, those with 2.5-3.5 points had a median survival of 3.2 months (all p-values ≤ 0.001). CONCLUSION: The LabBM score, which is derived from inexpensive blood tests and easy to use, stratified patients into three very distinct prognostic groups and deserves further validation.
BACKGROUND AND AIM: The prognostic assessment of patients referred for palliative radiotherapy can be conducted by site-specific scores. A quick assessment that would cover the whole spectrum could simplify the working day of clinicians who are not specialists for a particular disease site. This study evaluated a promising score, the LabBM (validated for brain metastases), in patients treated for other indications. MATERIALS AND METHODS: The LabBM score was calculated in 375 patients by assigning 1 point each for C-reactive protein and lactate dehydrogenase above the upper limit of normal, and 0.5 points each for hemoglobin, platelets and albumin below the lower limit of normal. Uni- and multivariate analyses were performed. RESULTS: Median overall survival gradually decreased with increasing point sum (range 25.1-1.1 months). When grouped according to the original three-tiered model, excellent discrimination was found. Patients with 0-1 points had a median survival of 15.7 months. Those with 1.5-2 points had a median survival of 5.8 months. Finally, those with 2.5-3.5 points had a median survival of 3.2 months (all p-values ≤ 0.001). CONCLUSION: The LabBM score, which is derived from inexpensive blood tests and easy to use, stratified patients into three very distinct prognostic groups and deserves further validation.
Authors: Monica S Krishnan; Zachary Epstein-Peterson; Yu-Hui Chen; Yolanda D Tseng; Alexi A Wright; Jennifer S Temel; Paul Catalano; Tracy A Balboni Journal: Cancer Date: 2013-10-02 Impact factor: 6.860
Authors: Linn M Åsli; Tor Å Myklebust; Stein O Kvaløy; Vidar Jetne; Bjørn Møller; Sverre G Levernes; Tom B Johannesen Journal: Acta Oncol Date: 2018-04-28 Impact factor: 4.089
Authors: Anna S Berghoff; Fabian Wolpert; Tim Holland-Letz; Romina Koller; Georg Widhalm; Brigitte Gatterbauer; Karin Dieckmann; Peter Birner; Rupert Bartsch; Christoph C Zielinski; Michael Weller; Matthias Preusser Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300
Authors: Susan Y Wu; Lisa Singer; Lauren Boreta; Michael A Garcia; Shannon E Fogh; Steve E Braunstein Journal: BMC Palliat Care Date: 2019-03-23 Impact factor: 3.234
Authors: Dirk Rades; Jon Cacicedo; Darejan Lomidze; Ahmed Al-Salool; Barbara Segedin; Blaz Groselj; Steven E Schild Journal: Cancers (Basel) Date: 2022-05-22 Impact factor: 6.575